Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0015674 (
chronic fatigue syndrome
)
2,978
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
In vitro activity of antimicrobial agents such as ABPC, SBPC, MPC, CEZ, CTM, CMZ, CTX, CMX, CZX, LMOX,
CPZ
,
CFS
and GM against major clinical isolates, S. aureus, S. pyogenes, E. coli, K. pneumoniae, P. mirabilis, C. freundii, Enterobacter spp., S. marcescens, P. vulgaris and P. aeruginosa, was examined. In this paper, we will report the susceptibility of S. aureus, S. pyogenes, E. coli, K. pneumoniae and P. mirabilis during a three-year period, 1981 to approximately 1983. CEZ- and GM-resistant S. aureus has markedly increased and occupied 24% and 18%, respectively, in 1983. CMZ and
CFS
have showed potent activity against CEZ-resistant S. aureus. It seems that the abuse of third generation-cephems and new oral cephalosporins is closely related with the increase of cephems-resistant S. aureus. The penicillin- and cephem-resistant strains of S. pyogenes could not be found in our study. Quite a few strains of E. coli, K. pneumoniae and P. mirabilis are resistant to penicillins, and also there is no appreciable change in susceptibility. Some strains of E. coli, K. pneumoniae and P. mirabilis showed low susceptibility to
CPZ
, but all strains showed high susceptibility and no change in susceptibility to third generations, and these strains showed no tendency to decrease in susceptibility to GM.
...
PMID:[Distribution and changes in the susceptibility of bacteria isolated from clinical samples. II]. 390 Apr 59
Fundamental and clinical studies were carried out on ceftazidime ( CAZ ), a newly synthesized cephalosporin C antibiotic ( CEPs ). The antibacterial activity of CAZ was compared with those of CER, CEZ, CMZ and
CPZ
against clinical isolates of S. aureus. S. pyogenes. E. coli, K. pneumoniae and P. mirabilis, and with those of GM and
CFS
against P. aeruginosa. Against S. aureus, the antibacterial activity of CER was highest, followed by that of CEZ. The peak MIC after inoculation of 100-fold dilution was 0.10 microgram/ml with CER and 0.78 microgram/ml with CEZ. But in view of the peak MIC of 6.25 micrograms/ml, the antibacterial activity of CAZ was inferior to that of
CPZ
by about 2 tubes. This was not surprising, because CAZ was one of the antibiotics in the fifth group of CEPs . The CEPs in the fifth group naturally show high antibacterial activity against S. pyogenes. CAZ , as expected, inhibited the growth of all the strains at the concentration of 0.10 microgram/ml at the inoculation of 100-fold dilution. In the gut bacterial flora such as E. coli, K. pneumoniae and P. mirabilis, CAZ showed the results almost equal to those of other CEPs in the fifth group; the peak MICs of CAZ were 0.20 approximately 0.39, 0.20 approximately 0.39, 0.10 microgram/ml, respectively, at the inoculation of 100-fold dilution, which was good results. In P. mirabilis with the undiluted inoculation, the result of CAZ was slightly inferior to those of the other CEPs in the fifth group previously reported; however, CAZ was prone to be affected by inoculum size, and with the inoculation of 100-fold dilution, MIC of CAZ turned to be as low as 0.10 microgram/ml. Against P. aeruginosa, CAZ showed the activity comparable to that of
CFS
, the antibiotic considered to have the highest antibacterial activity of all CEPs used in Japan. This finding is in accordance with the findings reported by other authors. The peak MICs of CAZ were 3.13, 12.5 microgram/ml at the inoculation of undiluted solution, and from 1.56 to 3.13 microgram/ml at the inoculation of 100-fold dilution, which were the results equal to, or even better than those of GM. The change in blood levels of CAZ was studied by one shot intravenous injection and 1 hour intravenous drip infusion.(ABSTRACT TRUNCATED AT 400 WORDS)
...
PMID:[Fundamental and clinical studies on ceftazidime in the field of pediatrics]. 637 54
In vitro activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections were investigated by dilution method using MIC 2000 (Dynatec) during July to October in 1982. The summarized results are as follows: PMPC and CCL have showed potent activities against E coli among the oral antimicrobial agents. PMPC and CCL at 3.13 micrograms/ml inhibited 90% of E. coli tested. CTM, CTX, CZX, CMX and LMOX at concentrations of 0.39 microgram/ml or less among the parenteral antimicrobial agents inhibited 90% of E. coli tested. The value of MIC90 (concentration at which 90% of isolates are inhibited) against K. pneumoniae results in the resistant range for ABPC, NA, CEX, CCL and ST. Among the parenteral cephems, CMX seemed most effective against K. pneumoniae tested. C. freundii seemed generally low susceptible to antimicrobial agents tested. Among the oral agents, PMPC, PPA and ST have showed moderate activity against C. freundii. Among the parenteral agents, CMX and LMOX also showed moderate activity against C. freundii, inhibiting 50% of the strains tested at 6.25 micrograms/ml. Among the oral agents, PMPC showed the most potent activity against E. cloacae. E. cloacae tested were highly resistant to the first and second generation cephems. Among the third generation, CMX seemed the most potent activity against E. cloacae isolated. However, CMX concentration of 1.56 micrograms/ml was necessary to inhibit 50% of tested E. cloacae. P. mirabilis tested was resistant to all oral antimicrobial agents except CCL and ST. The value of MIC90 of the first and second generation cephems against P. mirabilis results in the moderately susceptible range (6.25-25 micrograms/ml). The third generation seemed most effective against P. mirabilis tested. PMPC, NA, PPA and ST concentrations of 0.78-1.56 micrograms/ml were necessary to inhibit 50% of tested P. vulgaris. CEZ and CTM, seemed less potent activity than CFX and CMZ against P. vulgaris. CTX, CZX, CMX and LMOX except
CPZ
have showed potent activities against P. vulgaris, these at 0.1 micrograms/ml or less inhibited 50% of P. vulgaris tested. P. aeruginosa has been resistant to the third generation cephems except
CPZ
, but TOB, GM, AMK,
CFS
, PIPC and
CPZ
have showed high activities against P. aeruginosa, inhibiting 50% of the strains tested at 0.39-6.25 micrograms/ml. The oral antimicrobial agents, and first and second generation cephems had not showed significant activity against S. marcescens. And strains of S. marcescens were relatively susceptible to the third generation cephems.(ABSTRACT TRUNCATED AT 400 WORDS)
...
PMID:[Comparative studies of antimicrobial agents against causative organisms isolated from urinary tract infections (1982). I. Susceptibility distribution]. 643 64
In vitro susceptibilities have been investigated against several species isolated from patients with simple and complicated urinary tract infections (UTI) during 1980-1982. Antimicrobial activities of the third generation cephems against E. coli isolated from patients with complicated UTI were found to decrease slightly in 1982. And those against Klebsiella spp. isolated from patients with simple and complicated UTI were also found to decrease similarly. Against P. mirabilis, all the drugs tested have showed relatively potent activities and slight changes in the susceptibility. The marked decrease of susceptibility against Citrobacter spp. isolated from UTI have been found even in the third generation cephems. Especially, Citrobacter spp. exhibited a greater degree of resistant to CZX and
CPZ
. Strains of P. aeruginosa were on the whole susceptible to the drugs tested,
CFS
, GM, TOB and AMK, inhibiting 50-80% of the strains tested at 1.56 micrograms/ml. CTX, CZX and CMX seemed most effective against S. marcescens among the third generation cephems, inhibiting 50-90% of the strains tested at 3.13 micrograms/ml.
...
PMID:[Comparative studies of antimicrobial agents against causative organisms isolated from urinary tract infections (1982). III. Secular changes in susceptibility]. 643 65
Fundamental and clinical studies on cefpiramide (CPM), a new semisynthetic cephalosporin were performed and the following results were obtained. Antibacterial activity The antibacterial activity of CPM was investigated in comparison with those of CTT,
CPZ
, CEZ, LMOX and
CFS
. Against clinical isolates of S. aureus, CPM was superior to CTT and LMOX, but almost similar to
CPZ
and inferior to CEZ. Against E. coli, K. pneumoniae, P. mirabilis and S. marcescens, CPM showed the activity almost similar to that of CEZ, but inferior to those of the others. On the contrary, the activity of CPM against P. aeruginosa was satisfactory and was superior to those of CTT,
CPZ
and LMOX, but slightly inferior to that of
CFS
. Blood level and urinary recovery Twenty mg/kg of CPM was given intravenously at one shot to 3 patients. The mean serum levels of CPM were 116.9 micrograms/ml at 30 minutes, 90.5 micrograms/ml at 1 hour, 71.1 micrograms/ml at 2 hours, 55.8 micrograms/ml at 4 hours, 24.9 micrograms/ml at 6 hours, 19.3 micrograms/ml at 9 hours and 12.1 micrograms/ml at 12 hours after administration, respectively. The mean half-life was very long and the value was 3.85 hours. The urinary recovery rates in 2 cases were 18.31 and 21.47% respectively up to 12 hours after administration. Clinical results and side effects CPM was given intravenously to 30 diseases including 11 cases of bronchopneumonia, 3 cases of bronchopneumonia and pleurisy, 2 cases of bronchitis, 4 cases of purulent tonsillitis, 5 cases of pyelonephritis and each one case of pyothorax, parotitis, cellulitis, otitis media and salmonellosis. CPM was effective in 29 out of 30 cases, and the effective rate was 96.7%. As side effects, 2 cases of fever and 1 case of cough were observed, but no abnormality in clinical laboratory findings was observed.
...
PMID:[Experimental and clinical evaluation of cefpiramide in pediatrics]. 665 42